<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01675154</url>
  </required_header>
  <id_info>
    <org_study_id>3940</org_study_id>
    <secondary_id>FD-R-003940</secondary_id>
    <nct_id>NCT01675154</nct_id>
  </id_info>
  <brief_title>Phase 2 Study of Orlistat and SLx-4090 for the Treatment of Type 1 Hyperlipoproteinemia</brief_title>
  <official_title>Phase 2 Study of Orlistat and SLx-4090 for Teh Treatment of Type 1 Hyperlipoproteinemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Funding Source - FDA OOPD

      This study is being done to find out whether an investigational (not approved by FDA ) drug
      called SLx-4090 or Orlistat (FDA approved medication for weight loss) when given alone or in
      combination can treat the high blood fat (elevated triglycerides)levels found in the
      condition Type 1 Hyperlipoproteinemia (T1HLP) better or more safely than low fat diet alone,
      the current standard medical care.

      It is also not clear whether Orlistat, that is FDA approved for weight loss, is effective in
      lowering blood fat levels in patients with Type 1 hyperlipoproteinemia (T1HLP). The
      researchers are interested in learning whether any one of these drugs when given alone or in
      combination is more effective and safe in treating T1HLP.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Type I hyperlipoproteinemia is a rare, autosomal recessive metabolic disorder characterized
      by extreme hypertriglyceridemia due to a deficiency in lipoprotein lipase or related
      proteins. Treatment of these patients is challenging as triglyceride-lowering medications are
      ineffective. A low fat diet is helpful, however, despite good dietary compliance, some
      patients continue to have severe hypertriglyceridemia and recurrent pancreatitis which can be
      life threatening. Therefore, we wish to investigate whether inducing dietary fat
      malabsorption or inhibiting chylomicron formation will cause further lowering of serum
      triglycerides (TG) beyond the effect of limiting dietary fat intake.

      We will study the efficacy and safety of an inhibitor of intestinal lipase (Orlistat) and an
      intestinal-specific inhibitor of microsomal triglyceride transport protein (MTP) involved in
      the assembly and secretion of chylomicrons (SLx-4090), alone and in combination, for reducing
      serum triglyceride levels in patients with Type I hyperlipoproteinemia. We plan to enroll 20
      patients with Type I hyperlipoproteinemia in a randomized, double-blind, placebo-controlled,
      cross-over trial. After a baseline evaluation, the subjects will be randomly assigned to
      placebo/placebo, Orlistat/placebo, SLx-4090/placebo or Orlistat/SLx-4090 for the duration of
      four weeks followed by a one week wash out period. During the last week of each study period,
      fasting blood samples will be drawn for three consecutive days for serum lipids and chemistry
      panel. The primary endpoint will be serum triglycerides; the secondary endpoint variables
      will be fasting and postprandial serum chylomicron-TG levels, postprandial serum TG levels
      during a meal tolerance test and retinyl palmitate levels during a meal tolerance test.
      Repeated measures analysis of variance will be used for statistical comparisons.

      Our results may help in designing novel therapeutic approaches for patients with Type 1
      hyperlipoproteinemia.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">July 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in serum triglycerides from baseline for each crossover arm phase of placebo/placebo, orlistat/placebo, orlistat/SLx-4090, SLx-4090/placebo</measure>
    <time_frame>Every every 4 weeks at the end of each phase for 3 draws</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Type 1 Hyperlipoproteinemia</condition>
  <arm_group>
    <arm_group_label>SLx-4090 placebo/Orlistat Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Slx-4090(placebo) is dosed as 4 tablets of 50 mg, three times per day with meals.
Orlistat (placebo) is dosed as 2 capsules of 60 mg, three times per day with meals.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Orlistat/placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Orlistat two capsules 60mg each, three times per day with meals. Placebo for SLx-4090, 4 tablets 50mg each, three times per day with meals.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Orlistat placebo /Slx-4090</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Orlistat placebo 2 capsules, 60mg each three times per day with meals. Slx-4090 4 tablets, 50mg each. three times per day with meals.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Orlistat/SLx-4090</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Orlistat, 2 capsules 60 mg each, three times per day with meals. SLx-4090 4 tablets 50mg each, three times per day with meals.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SLx-4090 placebo</intervention_name>
    <arm_group_label>SLx-4090 placebo/Orlistat Placebo</arm_group_label>
    <arm_group_label>Orlistat/placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Orlistat Placebo</intervention_name>
    <arm_group_label>SLx-4090 placebo/Orlistat Placebo</arm_group_label>
    <arm_group_label>Orlistat placebo /Slx-4090</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Orlistat</intervention_name>
    <arm_group_label>Orlistat/placebo</arm_group_label>
    <arm_group_label>Orlistat/SLx-4090</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Slx-4090</intervention_name>
    <arm_group_label>Orlistat placebo /Slx-4090</arm_group_label>
    <arm_group_label>Orlistat/SLx-4090</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type I hyperlipoproteinemia.

          -  Fasting serum triglyceride levels of greater than 1000 mg/dL.

          -  Age &gt; 12 years

        Exclusion Criteria:

          -  Secondary hypertriglyceridemias due to diabetes, renal disease, hypothyroidism,
             alcoholism and drug therapy such as estrogens and estrogen analogues, steroids,
             HIV-protease inhibitors, retinoic acid derivatives and interferons.

          -  Pregnant or lactating women

          -  Significant liver disease (elevated transaminases &gt; 2 times upper limit of normal)

          -  Alcohol abuse (&gt; 7 drinks or 84 g per week for women and &gt; 14 drinks for men or 168 g
             per week for men)

          -  Drug use (cocaine, marijuana, LSD, etc.)

          -  Major surgery in the past three months

          -  Congestive heart failure

          -  Serum creatinine greater than 2.5 mg/dL

          -  Cancer within the past five years

          -  Gastrointestinal surgery in the past

          -  Current therapy with anti-coagulants, digoxin and anti-arrhythmics

          -  Chronic malabsorption syndromes

          -  Cholestasis

          -  Acute illnesses such as acute pancreatitis in the last 8 weeks
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abhimanyu Garg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT Southwestern Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Claudia Quittner, RN, BSN, MS</last_name>
    <phone>214-648-9296</phone>
    <email>claudia.quittner@utsouthwestern.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chandna Vasandani, Ph.D</last_name>
    <phone>214-648-5074</phone>
    <email>chandna.vasandani@utsouthwestern.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UT Southwestern Medical Center 5323 Harry Hines Blvd</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-8537</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Abhimanyu Garg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nivedita Patni, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia Quittner, RN</last_name>
      <phone>214-648-9296</phone>
      <email>claudia.quittner@utsouthwestern.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 27, 2012</study_first_submitted>
  <study_first_submitted_qc>August 28, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2012</study_first_posted>
  <last_update_submitted>June 16, 2017</last_update_submitted>
  <last_update_submitted_qc>June 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Abhimanyu Garg</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <keyword>hypertriglyceridemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipoproteinemias</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Orlistat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

